Neuland Laboratories Limited has announced its financial results for the quarter and year ended March 31, 2026. The company reported a strong fiscal year-end performance, fueled by significant growth in total income and profit margins. Management remains optimistic about future business visibility, citing strategic investments in Peptide Manufacturing and a new R&D Centre as core drivers for sustainable long-term growth.
Financial Highlights
For the fourth quarter ended March 31, 2026, Neuland Laboratories achieved a total income of ₹788.7 crore, reflecting a substantial 134.9% year-on-year increase. Profit after tax for the quarter surged to ₹212.5 crore, marking a 666.3% growth compared to the same period last year. The EBITDA for the quarter stood at ₹319.4 crore, with an impressive EBITDA margin of 40.5%.
Management Perspective
Commenting on the results, Saharsh Davuluri, CEO and Managing Director, stated that the company successfully met its expectations for the fiscal year. The leadership team noted that current business visibility is supported by a robust pipeline of commercial and near-commercial molecules. Execution discipline and customer satisfaction remain at the forefront of the company’s operational strategy.
Strategic Outlook and Investments
Neuland Laboratories is focused on expanding its capabilities beyond current horizons. Key strategic pillars for this growth include:
- Peptide Manufacturing: Continued investment to scale specialized production capabilities.
- R&D Expansion: Construction and operationalization of a new R&D Centre to drive innovation.
- Business Development: A targeted approach to securing projects that align with high-quality, sustainable growth objectives.
These initiatives are proceeding according to plan, ensuring the company remains well-positioned to support its global customer base across 80 countries.
Source: BSE
